Syngenta AG (ADR) (NYSE:SYT) rejected a bid from Monsanto Company (NYSE:MON), overtly stating that the offer was such that undervalued the Swiss firm. The offer didn’t quite take regulatory risks into account. A myriad of sources has affirmed that the Swiss firm has been offered a mere $45 billion.
About the proposed deal
Sources having knowledge on the talks revealed that if the agricultural companies ponder a purported takeover, then the investment bank dealing with the deal may see humongous sales exceeding $31 billion, as a combined value.
On Friday, sources at Syngenta corroborated that the board rejected a 45% cash offer made by Monsanto, evaluating to $486.35 for each share purchased. Fundamentally, the offer is slated to have undervalue the prospects of Syngenta, underestimating execution risks which includes multiple levels of public scrutiny across countries.
All cash deal
Syngenta was working closely with Goldman Sachs Group Inc (NYSE:GS) in order to assess the holistic merits of Monsanto sale. The latter approached Syngenta in 2014, when the company expressed intent in taking over the Swiss rival. The US treasury voiced against tax inversion. The company cannot re-domicile in Switzerland, and the transaction shall take place in cash, rather than stock.
Monsanto has a lot of profits in line, once the takeover of Syngenta is in place. The company has investments in R&D pipeline, with estimated expense in crop productivity, comprising sugar cane, soybeans, cereals or corn. Among all, Syngenta plays a pivotal role in ensuring crop protection. Hence, Monsanto circles the company to gain maximal returns and enhance profitability.
Antitrust regulators against the deal
The companies showed cultural affinities. However, the merger is challenged by a plethora of antitrust regulators in North America. Both the groups are leaders in the market, especially the seeds industry. Hence, the antitrust regulators, pondering market dominance, protest the collaborative venture.
